Bruker Corporation Stock News

Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.

Upgrades William Blair upgraded the previous rating for Foot Locker Inc (NYSE:FL) from Sell to Hold. For the second quarter, Foot Locker had an EPS of $1.10, compared to year-ago quarter EPS of $2.21.

BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.

Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.

Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.

Bruker Corporation (NASDAQ:BRKR ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Justin Ward - Senior Director of Investor Relations and Corporate Development Frank La

Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.

The Nasdaq has a reputation for being the home of aggressive hypergrowth companies — firms that can go up five- or tenfold in a year and sometimes crash just as quickly. Most investors probably woul

Waters (WAT) delivered earnings and revenue surprises of 4.56% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2022 financial results after market close on Wednesday, August 3, 202

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.